Literature DB >> 29102599

Differential effects of lipid biosynthesis inhibitors on Zika and Semliki Forest viruses.

Jamie Royle1, Claire L Donald1, Andres Merits2, Alain Kohl1, Margus Varjak3.   

Abstract

The recent outbreak of infection with Zika virus (ZIKV; Flaviviridae) has attracted attention to this previously neglected mosquito-borne pathogen and the need for efficient therapies. Since flavivirus replication is generally known to be dependent on fatty acid biosynthesis, two inhibitors of this pathway, 5-(tetradecyloxyl)-2-furoic acid (TOFA) and cerulenin, were tested for their potentiality to inhibit virus replication. At concentrations previously shown to inhibit the replication of other flaviviruses, neither drug had a significant antiviral affect against ZIKV, but reduced the replication of the non-related mosquito-borne Semliki Forest virus (Togaviridae).
Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Antiviral agent; Lipid biosynthesis; Semliki Forest virus; Zika virus

Mesh:

Substances:

Year:  2017        PMID: 29102599      PMCID: PMC5726355          DOI: 10.1016/j.tvjl.2017.10.009

Source DB:  PubMed          Journal:  Vet J        ISSN: 1090-0233            Impact factor:   2.688


Arboviruses are a diverse group of viruses that are transmitted by arthropod vectors, including mosquitoes, ticks and midges and belong to four main viral families (Togaviridae, Flaviviridae, Bunyaviridae and Reoviridae). In the Flaviviridae (genus Flavivirus), important and/or representative viruses include Zika virus (ZIKV) and dengue virus (DENV), whilst the genus Alphavirus in the Togaviridae family contains chikungunya virus (CHIKV) and Semliki Forest virus (SFV). Arbovirus infections can cause severe disease in a range of human and animal hosts, resulting in a significant social and economic impact in many areas of the world (Weaver and Reisen, 2010). The recent outbreak of infection with Zika virus (ZIKV, Flaviviridae) in human beings has brought increased attention to previously this neglected arboviruses. ZIKV is thought to be mainly spread by Aedes aegypti mosquitoes in the South American outbreak (Ferreira-de-Brito et al., 2016). Symptoms of infection in human beings are generally mild, consisting of fever and joint pain. However, infection during pregnancy can cause microcephaly and other manifestations that are grouped as Zika congenital syndrome, while infection in adults has been linked to Guillain-Barré syndrome (Russo et al., 2017). The replication of several flaviviruses, including DENV and alphaviruses (CHIKV), is dependent on continuous synthesis of fatty acids; the use of chemicals to inhibit their production has been shown to decrease virus production (Heaton et al., 2010, Karlas et al., 2016). These pathways are an attractive target for antiviral agents, as has been postulated for flaviviruses, including ZIKV (Martin-Acebes et al., 2016). Fatty acid synthesis in the cytoplasm of eukaryotic cells requires three different enzymes that act in an orchestrated manner: ATP citrate lyase (ACLY), acetyl-CoA carboxylase (ACC) and fatty acid synthase (FASN). Here we aimed to assess if ZIKV replication could be restricted through the treatment of infected cells with drugs that inhibit fatty acid biosynthesis. To this end we used 5-(tetradecyloxyl)-2-furoic acid (TOFA; Sigma–Aldrich) and cerulenin (Sigma–Aldrich), which inhibit ACC and FASN, respectively. Firstly, the toxicity of the drugs was tested on adenocarcinomic human alveolar basal epithelial (A549) cells grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% foetal bovine serum. Cell viability was assessed by measuring ATP levels using the CellTitre-Glo Luminescent Cell Viability Assay (Promega). At 8 h after the addition of the drug, cells treated with cerulenin exhibited reduced viability. This effect was more prominent after 24 h. However, treatment with TOFA did not decrease cell viability (Fig. 1A, top and lower panels).
Fig. 1

(A) A549 cells were treated with different concentrations of drugs for 8 or 24 h. Dimethyl sulphoxide (DMSO) was used as a negative control and cell viability was measured using a CellTitre-Glo Luminescent Cell Viability Assay kit. The experiment was repeated independently three times. (B) Representation of reporter viruses: (1) Zika virus expressing nanoluciferase (ZIKV-NlucUbi); and (2) Semliki Forest virus expressing firefly luciferase (SFV4(3H)-FFLuc). (C) A549 cells were infected with SFV4(3H)-FFLuc at a multiplicity of infection (MOI) of 1 and drugs were added at 1 h post-infection (hpi). After 8 hpi, the cells were lysed and firefly luciferase (FFLuc) activity was measured. (D) A549 cells were infected with ZIKV-NLucUbi at MOIs of 0.1 or 1 and drugs were added at 1, 4 or 16 h. Cells were lysed after either 12 or 24 hpi and nanoluciferase (Nluc) activity was measured. Experiments in (C) and (D) were conducted independently twice in quadruplicate; the relative mean values with standard errors are depicted. (E) A549 cells were infected with Brazilian ZIKV strain PE243 at a MOI of 1. Drugs were added either 1 or 4 hpi; total RNA was isolated at 12 or 24 hpi, respectively. Genomic RNA levels were analysed by reverse transcriptase quantitative PCR (RT-qPCR) using cellular glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene as an internal control. The experiment was repeated independently three times and the relative mean values with standard error are depicted. *P < 0.01 in Student’s t test.

(A) A549 cells were treated with different concentrations of drugs for 8 or 24 h. Dimethyl sulphoxide (DMSO) was used as a negative control and cell viability was measured using a CellTitre-Glo Luminescent Cell Viability Assay kit. The experiment was repeated independently three times. (B) Representation of reporter viruses: (1) Zika virus expressing nanoluciferase (ZIKV-NlucUbi); and (2) Semliki Forest virus expressing firefly luciferase (SFV4(3H)-FFLuc). (C) A549 cells were infected with SFV4(3H)-FFLuc at a multiplicity of infection (MOI) of 1 and drugs were added at 1 h post-infection (hpi). After 8 hpi, the cells were lysed and firefly luciferase (FFLuc) activity was measured. (D) A549 cells were infected with ZIKV-NLucUbi at MOIs of 0.1 or 1 and drugs were added at 1, 4 or 16 h. Cells were lysed after either 12 or 24 hpi and nanoluciferase (Nluc) activity was measured. Experiments in (C) and (D) were conducted independently twice in quadruplicate; the relative mean values with standard errors are depicted. (E) A549 cells were infected with Brazilian ZIKV strain PE243 at a MOI of 1. Drugs were added either 1 or 4 hpi; total RNA was isolated at 12 or 24 hpi, respectively. Genomic RNA levels were analysed by reverse transcriptase quantitative PCR (RT-qPCR) using cellular glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene as an internal control. The experiment was repeated independently three times and the relative mean values with standard error are depicted. *P < 0.01 in Student’s t test. Secondly, to study the inhibitory effect of these drugs on ZIKV replication, A549 cells were infected with a generic Asian strain-derived ZIKV expressing nanoluciferase (Nluc) followed by foot-and-mouth disease virus 2A autoprotease, ubiquitin sequence (Fig. 1B); these elements are required to liberate Nluc from duplicated capsid protein C. The cells were infected at a multiplicity of infection (MOI) of 0.1 or 1 and the drugs applied at either 4 or 16 h post-infection (hpi), respectively. Due to the toxicity of cerulenin, cells were lysed 8 h post-treatment and Nluc activity was measured using the Nano-Glo kit (Promega). We also compared ZIKV to a recombinant strain of SFV expressing cleavable firefly luciferase (FFLuc; designated SFV4(3H)-FFLuc) (Fig. 1B). A549 cells were infected at a MOI of 1 and drugs were added 1 hpi. As expected, both cerulenin and TOFA inhibited SFV; this effect was concentration dependent, since higher concentrations resulted in reduced luciferase amounts (Fig. 1C). Similar effects have been shown previously for CHIKV (Karlas et al., 2016), a close relative of SFV. The results of TOFA treatment on ZIKV showed that, if Nluc levels were measured 12 hpi (Fig. 1D, MOI 1, drugs added at 4 hpi) at the highest drug concentration, only a 20% reduction in Nluc levels was observed, thus indicating a weak decrease in ZIKV replication. This weak effect was also present when cells were lysed at 24 hpi (Fig. 1D, MOI 0.1, drugs added at 16 hpi). However, regardless of the concentration of cerulenin used, there was no decrease in Nluc levels. This suggested there was no effect of this drug on ZIKV replication. These results were unexpected, since the dependence of flaviviruses on lipid biosynthesis is well documented. We therefore performed a further experiment, whereby A549 cells were infected at a MOI of 1, with drugs added at 1 hpi and Nluc activity measured at 24 hpi. TOFA was again found to have antiviral effects only at the highest concentration, resulting in a weak, non-significant, 20% reduction in luciferase (Fig. 1D). However, despite its observed toxicity, cerulenin did not decrease virus replication. To confirm these findings, cells were infected with the wild-type Brazilian strain ZIKV PE243 (Donald et al., 2016) at an MOI of 1. Cells were then treated with both drugs either at 1 or 4 hpi and total RNA was collected at 12 or 24 hpi. Using reverse transcriptase (RT) quantitative PCR (RT-qPCR), we found that neither cerulenin nor TOFA decreased virus genomic RNA levels significantly (except for a weak reduction at 12 hpi with cerulenin), thereby suggesting that neither drug affects virus replication (Fig. 1E). The resistance of ZIKV in A549 cells under the conditions tested here was unexpected, since dependence on ACC and FASN has been shown for different flaviviruses including DENV and hepatitis C virus (HCV) (Yang et al., 2008, Heaton et al., 2010). However, both DENV and HCV infections are known to increase production of fatty acids and higher levels of FASN expression. It is therefore possible that heightened production of FASN could occur in ZIKV infected cells, which may result in relative insensitivity to drugs. Both drugs had the expected antiviral effects against SFV infection and targeting fatty acids synthesis may be one way to treat alphavirus infections. However, a more detailed analysis of the metabolic activities in cells associated with ZIKV is required.

Conflict of interest statement

None of the authors of this paper has a financial or personal relationship with other people or organisations that could inappropriately influence or bias the content of the paper.
  7 in total

Review 1.  Lipids and flaviviruses, present and future perspectives for the control of dengue, Zika, and West Nile viruses.

Authors:  Miguel A Martín-Acebes; Ángela Vázquez-Calvo; Juan-Carlos Saiz
Journal:  Prog Lipid Res       Date:  2016-10-01       Impact factor: 16.195

2.  Dengue virus nonstructural protein 3 redistributes fatty acid synthase to sites of viral replication and increases cellular fatty acid synthesis.

Authors:  Nicholas S Heaton; Rushika Perera; Kristi L Berger; Sudip Khadka; Douglas J Lacount; Richard J Kuhn; Glenn Randall
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-20       Impact factor: 11.205

Review 3.  Present and future arboviral threats.

Authors:  Scott C Weaver; William K Reisen
Journal:  Antiviral Res       Date:  2009-10-24       Impact factor: 5.970

4.  Fatty acid synthase is up-regulated during hepatitis C virus infection and regulates hepatitis C virus entry and production.

Authors:  Wei Yang; Brian L Hood; Sara L Chadwick; Shufeng Liu; Simon C Watkins; Guangxiang Luo; Thomas P Conrads; Tianyi Wang
Journal:  Hepatology       Date:  2008-11       Impact factor: 17.425

5.  A human genome-wide loss-of-function screen identifies effective chikungunya antiviral drugs.

Authors:  Alexander Karlas; Stefano Berre; Thérèse Couderc; Margus Varjak; Peter Braun; Michael Meyer; Nicolas Gangneux; Liis Karo-Astover; Friderike Weege; Martin Raftery; Günther Schönrich; Uwe Klemm; Anne Wurzlbauer; Franz Bracher; Andres Merits; Thomas F Meyer; Marc Lecuit
Journal:  Nat Commun       Date:  2016-05-12       Impact factor: 14.919

6.  Full Genome Sequence and sfRNA Interferon Antagonist Activity of Zika Virus from Recife, Brazil.

Authors:  Claire L Donald; Benjamin Brennan; Stephanie L Cumberworth; Veronica V Rezelj; Jordan J Clark; Marli T Cordeiro; Rafael Freitas de Oliveira França; Lindomar J Pena; Gavin S Wilkie; Ana Da Silva Filipe; Christopher Davis; Joseph Hughes; Margus Varjak; Martin Selinger; Luíza Zuvanov; Ania M Owsianka; Arvind H Patel; John McLauchlan; Brett D Lindenbach; Gamou Fall; Amadou A Sall; Roman Biek; Jan Rehwinkel; Esther Schnettler; Alain Kohl
Journal:  PLoS Negl Trop Dis       Date:  2016-10-05

7.  First detection of natural infection of Aedes aegypti with Zika virus in Brazil and throughout South America.

Authors:  Anielly Ferreira-de-Brito; Ieda P Ribeiro; Rafaella Moraes de Miranda; Rosilainy Surubi Fernandes; Stéphanie Silva Campos; Keli Antunes Barbosa da Silva; Marcia Gonçalves de Castro; Myrna C Bonaldo; Patrícia Brasil; Ricardo Lourenço-de-Oliveira
Journal:  Mem Inst Oswaldo Cruz       Date:  2016-10-03       Impact factor: 2.743

  7 in total
  4 in total

Review 1.  Host-Directed Antiviral Therapy.

Authors:  Naveen Kumar; Shalini Sharma; Ram Kumar; Bhupendra N Tripathi; Sanjay Barua; Hinh Ly; Barry T Rouse
Journal:  Clin Microbiol Rev       Date:  2020-05-13       Impact factor: 26.132

2.  A Human and Rhesus Macaque Interferon-Stimulated Gene Screen Shows That Over-Expression of ARHGEF3/XPLN Inhibits Replication of Hepatitis C Virus and Other Flavivirids.

Authors:  Connor G G Bamford; Elihu Aranday-Cortes; Ricardo Sanchez-Velazquez; Catrina Mullan; Alain Kohl; Arvind H Patel; Sam J Wilson; John McLauchlan
Journal:  Viruses       Date:  2022-07-28       Impact factor: 5.818

Review 3.  Intracellular Interactions Between Arboviruses and Wolbachia in Aedes aegypti.

Authors:  Jerica Isabel L Reyes; Yasutsugu Suzuki; Thaddeus Carvajal; Maria Nilda M Muñoz; Kozo Watanabe
Journal:  Front Cell Infect Microbiol       Date:  2021-06-23       Impact factor: 5.293

4.  Emerging viruses of zoonotic and veterinary importance.

Authors:  B A Blacklaws; J M Daly
Journal:  Vet J       Date:  2017-12-30       Impact factor: 2.688

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.